Indian Perspective on Antiplatelet De-escalation from Dual Antiplatelet Therapy to Single Antiplatelet Therapy – INDEPTH INSIGHT Survey
Cardiology and Cardiovascular Medicine · 2026 · 10 (3)
DOI: 10.26502/fccm.92920490 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiology and Cardiovascular Medicine, 2026. Verfasst von Jagdish Chander Mohan und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Dual antiplatelet therapy (DAPT) is used for secondary prevention after percutaneous coronary intervention (PCI), but prolonged use raises bleeding risk.De-escalation to single antiplatelet therapy balances ischemic protection and safety.
Objective
This study aimed to assess cardiologists' knowledge, decisionmaking, treatment preferences and prescribing behaviors related to antiplatelet de-escalation in the Indian context.
Methods
A cross-sectional survey involving 384 Indian cardiologists with 18 questions assessed awareness of genetic and platelet testing, de-escalation, clopidogrel resistance, and adverse events.Participation was voluntary, and responses were analyzed descriptively to reduce bias.
Results
The survey demonstrated that 46.9% considered genetic testing relevant.However, its routine use remains limited, with greater reliance on platelet function testing (64.3%) and clinical judgement.High bleedingrisk (HBR) patients without genetic testing often switch to clopidogrel after 1-3 months (62.0%), while non-HBR patients typically use ticagrelor/prasugrel for 12 months (52.3%).Management of clopidogrel resistance followed guidelines, with 76.3% switching to another P2Y12 inhibitor.Most reported occasional (35.4%) transitions to prasugrel/ ticagrelor, while ticagrelor-to-clopidogrel switches were rare (38.5%).Adverse events (AEs) prompted therapy changes, with dyspnea (58.6%) being most common, leading to switching to clopidogrel.Major bleeding (70.4%), age ≥75 (39.2%), and low body weight (
Zitieren
APA
Mohan, J. C., Oomman, A., Shah, V. T., & Nath, B. (2026). Indian Perspective on Antiplatelet De-escalation from Dual Antiplatelet Therapy to Single Antiplatelet Therapy – INDEPTH INSIGHT Survey. Cardiology and Cardiovascular Medicine, 10(3). https://doi.org/10.26502/fccm.92920490
Vancouver
Mohan JC, Oomman A, Shah VT, Nath B. Indian Perspective on Antiplatelet De-escalation from Dual Antiplatelet Therapy to Single Antiplatelet Therapy – INDEPTH INSIGHT Survey. Cardiology and Cardiovascular Medicine. 2026;10(3). doi:10.26502/fccm.92920490
BibTeX
@article{Mohan2026,
author = {Mohan, Jagdish Chander and Oomman, Abraham and Shah, V T and Nath, Baishali},
title = {Indian Perspective on Antiplatelet De-escalation from Dual Antiplatelet Therapy to Single Antiplatelet Therapy – INDEPTH INSIGHT Survey},
journal = {Cardiology and Cardiovascular Medicine},
year = {2026},
volume = {10},
number = {3},
doi = {10.26502/fccm.92920490}
}
EUVIMED